To emulate the human mind's cognitive powers, Definiens used patented image segmentation and classification processes, and developed a method to render knowledge in a semantic network.
It uses the color, shape, texture and size of objects as well as their context and relationships to draw conclusions and inferences, similar to human analysis.
[3] In 2014, Definiens was acquired by MedImmune, the global biologics research and development arm of AstraZeneca, for an initial consideration of $150 million.
[6] The central concept behind Definiens Tissue Studio is a user interface that facilitates machine learning from example digital histopathology images in order to derive an image analysis solution suitable for the measurement of biomarkers and/or histological features within pre-defined regions of interest on a cell-by-cell basis, and within sub-cellular compartments.
Membership is distributed globally and user conferences are held regularly, the last having taken place in November 2009 in Munich, Germany.